Results 131 to 140 of about 27,196 (258)

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. [PDF]

J Immunother Cancer
Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J.   +26 more
europepmc   +1 more source

Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma

Clinical &Experimental Allergy, EarlyView.
Forced oscillometry technique defined small airways dysfunction as a treatable trait in asthma. Monoclonal antibodies can improve small airways dysfunction, but their effects vary by mechanism of action. ABSTRACT Small airways dysfunction (SAD) is a recognised treatable trait within severe asthma, associated with worse symptom control and increased ...
Robert Greig, Philipp Suter, Rory Chan, Brian Lipworth   +3 more
wiley   +1 more source

Vaccination during bispecific antibody treatment for myeloma. [PDF]

Blood Adv
Banerjee R, Raje NS.
europepmc   +1 more source

Plasmacytic markers as immunotherapeutic targets for primary CD20‐negative aggressive B‐cell lymphomas

British Journal of Haematology, EarlyView.
Frank Neumann, Claudia Schormann, Onur Cetin, Igor A. Kos, Moritz Bewarder, Eva C. Schwarz, Stefan Lohse, Stephanie Maurer, Philipp B. Staber, Joerg T. Bittenbring, Sigrun Smola, Konstantinos Christofyllakis, Markus Hoth, Lorenz Thurner   +13 more
wiley   +1 more source

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Systematic characterization of lysine glucuronidation in a bispecific antibody. [PDF]

MAbs
Reyda MR, Ji Q, Huang M, Sokolowska I, Yan Q, Mulholland J, Mo J, Hu P.   +7 more
europepmc   +1 more source

Is universal CAR T‐cell referral absolutely required for transplant‐ineligible patients with primary refractory or early relapsed DLBCL?

British Journal of Haematology, EarlyView.
Maria Dimou, Theodoros P. Vassilakopoulos   +1 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab. [PDF]

Cancer Discov
Mishra A, Meador CB, Kikkeri K, Cunneely Q, Lin M, Carmona-LaSalle TJ, Huang SB, Bell R, Putaturo V, Xia W, Liang JH, Fang J, San Vicente S, Zielinski CE, Digumarthy SR, Hung YP, Yeap BY, Edd JF, Lawrence MS, Sade-Feldman M, Sen DR, Toner M, Maheswaran S, Gainor JF, Haber DA.   +24 more
europepmc   +1 more source